CMS said Medicare will pay for one brain beta-amyloid imaging test per patient as a means to exclude Alzheimer's disease in narrowly defined diagnoses or to aid clinical trials of treatments or prevention strategies. Medicare will not offer widespread coverage of the costly test, used to find brain plaques linked to Alzheimer's disease. An advisory panel had questioned whether the scans would change outcomes for patients with early symptoms of cognitive decline.

Related Summaries